GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS - Nasdaq

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS  Nasdaq

Filgotinib 100 mg and 200 mg Plus Methotrexate Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone--. --Filgotinib.